What Джадену Treats: Main Uses and Benefits

---

The core therapeutic role of Джадену (Deferasirox) is the long-term management of chronic iron overload (hemosiderosis), a condition where excessive iron accumulates in the body's organs and tissues. The general benefit of treatment is the removal of this toxic iron burden, contributing to reducing the risk of serious health complications.

Management of Iron Accumulation

The medication is commonly used for patients, including adults and children (aged 2 years and older), who have developed excess iron associated with the need for blood transfusions due to chronic conditions like beta-thalassemia or Sickle Cell Disease. It is also considered relevant for managing chronic iron overload in select patients with Non-Transfusion-Dependent Thalassemia (NTDT) syndromes. By helping to achieve a sustained reduction in toxic iron levels, the therapy provides supportive relief that generally helps ease the overall symptom burden associated with systemic imbalance.

Protection and Functional Support

The key therapeutic goal is to help manage the risk of progressive damage that accumulated iron may cause in vital organs, particularly the heart and liver. By targeting and removing excess iron from these tissues, the therapy may help lower the risk of severe complications, including cardiac failure and liver fibrosis. This assists with supporting the patient's overall function and contributes to general well-being during symptomatic phases.

Quick Fact: Relief for Toxic Iron Accumulation	Therapeutic Focus	Indication Context	Primary Benefit
Iron Overload	Associated with the need for blood transfusions or NTDT syndromes	Assists with supporting functional stability and general well-being during symptomatic phases

The management of this condition is considered relevant to help support a sense of stability when symptoms of systemic imbalance are more noticeable.

Regulatory References

1. NIH DailyMed label for Deferasirox

Eligibility Map: Who can and cannot use Джадену (Deferasirox) — Official Regulatory Information

---

Eligibility Scope

Category	Regulatory Status
Allowed Populations	Adults and pediatric patients mathbfge 2 years of age (Transfusional Iron Overload). Patients mathbfge 10 years of age (Non-Transfusion-Dependent Thalassemia).
Not Recommended	Children less than 2 years of age (use not established). Pregnant and lactating women. Patients with Severe Hepatic Impairment (Child-Pugh Class C).
Contraindicated	Patients with Estimated GFR < 40 mL/ min/1.73 m^2 or creatinine clearance < 40 mL/ min. Patients with high-risk Myelodysplastic Syndromes (MDS) or advanced malignancies.

---

Condition-Specific Eligibility Rules

Official labeling contraindicates use based on organ function, specifically severe renal impairment (eGFR < 40 mL/ min/1.73 m^2) and conditions such as platelet counts less than 50 imes 10^9/ L. Use is avoided in severe hepatic impairment (Child-Pugh C) and requires special caution or dose reduction for moderate hepatic or renal impairment. Eligibility for pediatric patients is strictly defined by the minimum age for each specific iron overload indication.

---

Eligibility Classifications (High-Level)

Classification	Basis
Contraindicated	Renal function, platelet count, specific malignancies.
Not Recommended	Severe hepatic impairment, pregnancy, children < 2 years.
Restricted/Conditional	Moderate hepatic or renal impairment, older adults (ge 65 years).

Connection to the overall eligibility profile: Regulatory documents define who can and cannot use the medicine by establishing clear limits based on organ function, specifically prohibiting use in cases of severe renal impairment or severe hepatic impairment. Age is a defining factor, with the official label establishing different minimum age thresholds for specific indications and stating that use is not established below 2 years of age. These official statements delineate the patient populations that are permitted, restricted, or absolutely prohibited from receiving the medicine.

Джадену (Deferasirox) interaction profile is defined by specific regulatory restrictions, primarily concerning co-administration with substances that affect its efficacy or increase the risk of serious complications.

---

Documented Interaction Restrictions

Combinations to be Avoided The use of aluminum-containing antacid preparations is contraindicated because this co-administration is documented to interfere with Deferasirox's chelating action, which reduces its systemic availability and overall efficacy. Additionally, co-administration must be avoided with Potent UGT Inducers, which includes agents such as rifampicin, phenytoin, phenobarbital, and ritonavir, as these agents are formally documented to decrease Deferasirox systemic exposure. Similarly, the bile acid sequestrant cholestyramine should be avoided as it also reduces the drug's systemic levels.

Pharmacodynamic and Population Risk Co-administration with Ulcerogenic/Hemorrhagic Agents, including NSAIDs, corticosteroids, oral bisphosphonates, and anticoagulants, carries a documented risk of increased gastrointestinal hemorrhage, ulceration, and perforation. Regulatory labeling notes that this risk is particularly relevant and potentially greater in the elderly patient population.

Exposure Changes to Other Medicines Deferasirox is documented to alter the clearance of certain co-administered medicines. Specifically, it acts as an inhibitor that increases the systemic exposure of the CYP2C8 substrate repaglinide and the CYP1A2 substrate theophylline. Furthermore, official prescribing information states that Deferasirox increases the exposure of busulfan.

Selective Binding and Scavenging of Ferric Iron

The primary mechanism involves the drug acting as a tridentate chelating agent with a high molecular affinity for ferric iron ( Fe^3+), particularly the circulating Non-Transferrin-Bound Iron (NTBI). This targeted chemical binding results in the immediate neutralization of the free iron, thereby mitigating its capacity to initiate the Fenton reaction and generate damaging free radicals throughout the body. The immediate physiological effect is a reduction in the source of oxidative stress, which limits the susceptibility of circulating components and cell membranes to damage catalyzed by free iron.

Mobilization of Tissue Iron and Biliary Excretion

The mechanism extends beyond the bloodstream, as the drug’s lipophilic structure allows it to access and mobilize excess iron sequestered within intracellular pools of organs, such as the heart and liver. The resulting stable, water-soluble iron-drug complex is then processed via hepatic glucuronidation and systematically eliminated almost entirely through the biliary system into the feces.

Net Negative Iron Balance and Impact Mitigation

By causing the removal of iron from both circulation and organ tissues, the mechanism establishes a sustained net negative iron balance in the body. The fundamental physiological consequence is the mitigation of the impact of iron accumulation, which otherwise leads to chronic oxidative stress. This systemic action results in the reduction of the iron burden.

How to Use Джадену (Deferasirox)

Джадену is prescribed as a once-daily oral medication for the long-term management of chronic iron overload. The key principle of use is a continuous daily schedule taken at approximately the same time each day to maintain consistent drug levels.

---

Dosing and Frequency

Administration is via the oral route, and the dose is calculated strictly based on the patient's body weight (mg/kg) and the underlying indication. For transfusion-dependent iron overload, the initial dose is typically 14 mg/kg once daily. For Non-Transfusion-Dependent Thalassemia (NTDT), the initial daily dose is 7 mg/kg. Subsequent adjustments, made in increments of 3.5 mg/kg to 7 mg/kg, are based on serum ferritin levels. The maximum recommended dose for the transfusion-dependent indication is typically 28 mg/kg per day.

---

Administration and Preparation

The medicine is available as film-coated tablets and granules for oral suspension. The drug may be taken with or without a light meal. Tablets must be swallowed whole with water and must not be chewed, crushed, or divided to ensure proper delivery. Granules must be mixed with soft food (such as applesauce or yogurt) or specific liquids (apple or orange juice) and consumed immediately; they must not be mixed with water, milk, or carbonated drinks.

---

Population-Specific and Missed Dose Guidance

Instructions detail modifications for specific populations. The medication is used in the pediatric population aged two years and older. For patients with moderate hepatic impairment, a dose reduction—such as halving the initial dose—is required. If a dose is missed, it should be taken as soon as possible on that same day, and the patient must not double the dose the next day.

Research Evidence / Overview of Studies for Джадену (Deferasirox)

This section provides a factual overview of the clinical research and evidence structure for Deferasirox (the active ingredient in Джадену), describing what types of studies were conducted, what the research monitored, and what aspects remain uncertain, without offering clinical advice, dosing recommendations, or claims about efficacy.

---

Evidence for Chronic Iron Overload in Transfusion-Dependent Patients

The most extensive research base focuses on chronic iron overload that was associated with receiving regular blood transfusions over time. The available evidence for Deferasirox is derived from pivotal Phase III Randomized Controlled Trials (RCTs) in adults and children aged ge 2 years with underlying conditions such as beta-thalassemia and Sickle Cell Disease.

The research primarily monitored outcomes related to iron levels, most importantly by measuring Liver Iron Concentration (LIC), assessed by specialized scanning methods, and by tracking the blood marker Serum Ferritin (SF). Findings from these trials describe measurements related to the maintenance or reduction of LIC and SF levels over the observation period in the studied populations.

---

Research Examining Comparison with Older Chelation Therapies (Deferoxamine)

Clinical research was studied for how the measured outcomes of Deferasirox compared to those of the older, injectable treatment, Deferoxamine (DFO), in randomized settings. Researchers monitored changes in LIC and, in some trials, changes in cardiac iron concentration (T2* cardiac MRI). Studies report measurements in relation to the two therapies over the observation period.

---

What is Still Uncertain about Deferasirox Research

Regulatory reviews note several limitations where long-term effects are not fully established.

• Clinical Endpoints: There is limited information for long-term outcomes regarding the impact on final disease progression, such as overall survival or the prevention of major complications like heart failure, which are outcomes reflecting daily functioning or activity level that typically require decades of follow-up.
• Uncertainty: Because the research for Non-Transfusion-Dependent Thalassemias (NTDT) was approved under a specific regulatory pathway, further studies are required to fully verify and describe the long-term clinical findings in that population.

Key Studies & References

1. A randomized, open-label, multicenter study of deferasirox vs. deferoxamine in patients with $beta$-thalassemia and transfusional hemosiderosis

Common questions about Джадену (FAQ)

---

Q: How long does one need to take Джадену to see any changes?

Official administration guidelines state that adjustments to the dose are based on measurements of serum ferritin concentrations in the blood. This lab work is recommended to be monitored monthly. The response is evaluated by monitoring changes over time, and dose adjustments may occur every three to six months based on the therapeutic need.

---

Q: Can Джадену be taken with vitamins or supplements?

Official prescribing information specifically cautions against taking the medicine with aluminum-containing antacid preparations, as this can reduce the drug's effectiveness. Certain other medicines that can change how the body processes the drug, like specific UGT inducers, are also noted as potential interactions. Official documents do not provide general guidance on all supplements, and their use should be discussed with a healthcare professional.

---

Q: What is known about stopping Джадену treatment?

Regulatory guidance indicates that treatment may be temporarily interrupted to prevent iron levels from becoming too low, a condition called overchelation. This typically occurs if serum ferritin concentrations consistently fall below a certain threshold. During such an interruption, continued monthly monitoring of iron levels is observed, and therapy may be restarted based on the patient's iron status.

---

Q: Can Джадену cause fatigue or drowsiness?

Regulatory information notes that both drowsiness and fatigue (feeling very tired) have been reported as possible adverse reactions during clinical research. It is important for patients to be aware that these effects may occur while taking the medicine.

---

Q: Is there a risk of allergic reaction to Джадену?

Official prescribing information states that the medicine is contraindicated, meaning it should not be used, if a patient has a known hypersensitivity to the active ingredient or other components. Regulatory warnings also note that serious hypersensitivity or allergic-type reactions have been reported in connection with this medicine.

---

Q: What does the phrase 'plasma concentration' mean for Джадену?

In the context of this medicine, the phrase 'plasma concentration' refers to the measured amount of the active substance circulating in the liquid part of the blood (plasma). The active ingredient is highly attached to a protein in the plasma called serum albumin. This measurement reflects the amount of the active substance circulating in the body.

---

Q: Does Джадену affect blood sugar levels?

Official labeling indicates that this medicine is documented to change the way the body handles the diabetes medication repaglinide, potentially increasing its systemic presence. For this reason, official instructions note that if repaglinide is being used, closer monitoring of blood sugar (glucose) levels may be indicated.

---

Q: Is it true that Джадену can affect vision?

Official regulatory information mentions that ocular abnormalities and changes in vision may be associated with the use of this medicine. Due to this potential risk, official guidelines recommend that patients undergo annual ophthalmologic (eye) examinations during the course of treatment.

---

Q: Can Джадену interact with alcohol?

Some official patient information and regulatory guidance sheets advise patients not to consume alcohol while taking the active ingredient in Джадену.

---

Q: Are there official warnings about driving while taking Джадену?

Regulatory safety documents state that patients who experience side effects such as dizziness or drowsiness are advised to exercise caution. This caution applies specifically to activities like operating machinery or driving a vehicle.

---

Q: How often should one have lab tests during treatment with Джадену?

Official guidelines for safety monitoring describe that laboratory tests for key organ functions, including both kidney and liver function, are required. These blood tests, which track markers like serum creatinine and transaminases, are recommended to be performed at least monthly during the course of treatment.

---

Q: Can Джадену be taken if I already have heart problems?

The primary function of this medicine is to manage excess iron that can accumulate in organs, including the heart, which is a vital concern in iron overload conditions. Clinical research for this medicine has specifically monitored outcomes related to cardiac iron concentration to assess the drug's action in this area. Official eligibility criteria primarily define restrictions based on the function of the kidneys and liver.

---

Q: Is it true that Джадену can affect cholesterol levels?

While the medicine's main purpose is iron management, official labeling states that it can have documented interactions with specific medicines used to lower cholesterol, such as simvastatin. For example, one documented interaction involves reducing the systemic exposure of the bile acid sequestrant cholestyramine.

---

Q: What is the official status of Джадену?

Джадену (Deferasirox) is designated by major regulatory bodies globally, including the US FDA and the European EMA, as a prescription-only medicine (Rx-only). This status means that the medicine is classified as requiring strict physician oversight and supervision for use.

How to Store and Dispose of Джадену

Official regulatory labeling dictates specific conditions for the storage and disposal of JADENU (deferasirox) tablets and granules.

---

Storage Requirements

The medicine must be stored at controlled room temperature, specifically between 20^circC and 25^circC (68^circF and 77^circF). To protect the product, the original container must be kept closed tightly and stored away from moisture. JADENU must be stored out of the reach of children.

Stability and Handling

JADENU Sprinkle granules, once mixed with soft food, must be administered immediately and cannot be saved for later use. This ensures product stability and correct use.

Disposal Instructions

Any unused or expired JADENU product should be disposed of according to local regulations or through an authorized drug take-back program. The medicine should not be flushed down a toilet or poured into a drain unless explicitly instructed by a regulatory authority.